Table 2.
Blood pressure, glycemic and lipid lowering agents by impaired GFR status.
| Medications | Total N = 30,377 |
Impaired GFR <60 mL/min/1.73 m2 N = 11,909 |
Non-impaired GFR ≥60 mL/min/1.73 m2 N = 18,468 |
P value |
|---|---|---|---|---|
| Blood pressure lowering agents | ||||
| Using any blood pressure lowering agents | 22148 (72.9%) | 9668 (81.2%) | 12480 (67.6%) | <0.001 |
| (i) Diuretics | 6360 (20.9%) | 3168 (26.6%) | 3192 (17.3%) | <0.001 |
| (ii) Antiadrenergic drugs | 6139 (20.2%) | 3007 (25.2%) | 3132 (17%) | <0.001 |
| (iii) Calcium channel blockers | 11418 (37.6%) | 5525 (46.4%) | 5893 (31.9%) | <0.001 |
| (iv) ACEI/ARB | 16447 (54.1%) | 6369 (53.5%) | 10078 (54.6%) | 0.063 |
| (v) Vasodilators | 1009 (3.3%) | 739 (6.2%) | 270 (1.5%) | <0.001 |
| Glycemic lowering agents | ||||
| Using any glycemic lowering agents | 29317 (96.5%) | 11328 (95.1%) | 17989 (97.4%) | <0.001 |
| (i) Biguanides | 21591 (71.1%) | 6143 (51.6%) | 15448 (83.6%) | <0.001 |
| (ii) Sulfonylurea | 19524 (64.3%) | 6716 (56.4%) | 12808 (69.4%) | <0.001 |
| (iii) Thiazolidinedione | 2527 (8.3%) | 906 (7.6%) | 1621 (8.8%) | <0.001 |
| (iv) Alpha-glucosidase inhibitor | 189 (0.6%) | 65 (0.5%) | 124 (0.7%) | 0.174 |
| (v) DPP-4 inhibitors | 209 (0.7%) | 89 (0.7%) | 120 (0.6%) | 0.315 |
| (vi) GLP-1 agonists | 18 (0.1%) | 8 (0.1%) | 10 (0.1%) | 0.649 |
| (vii) Insulin | 6893 (22.7%) | 3875 (32.5%) | 3018 (16.3%) | <0.001 |
| Lipid lowering agents | ||||
| Using any lipid lowering agents | 21835 (71.9%) | 8723 (73.2%) | 13112 (71%) | <0.001 |
| (i) Statin | 18205 (59.9%) | 7176 (60.3%) | 11029 (59.7%) | 0.351 |
| (ii) Fibrate | 4242 (14%) | 1810 (15.2%) | 2432 (13.2%) | <0.001 |
All values are expressed as percentage.
Abbreviation: ACEI: angiotensin converting enzyme inhibitor; ARB: angiotensin receptor blocker; DPP-4 inhibitors: dipeptidyl peptidase-4 inhibitors; GLP-1 agonist: glucagon-like peptide 1 receptor agonists.